See more : Thirumalai Chemicals Limited (TIRUMALCHM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chengdu Olymvax Biopharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- EcoRub AB (publ) (ECO-B.ST) Income Statement Analysis – Financial Results
- UMW Holdings Berhad (4588.KL) Income Statement Analysis – Financial Results
- Block Energy Plc (BLOE.L) Income Statement Analysis – Financial Results
- Goldsource Mines Inc. (GXS.V) Income Statement Analysis – Financial Results
- Idemitsu Kosan Co.,Ltd. (IDKOF) Income Statement Analysis – Financial Results
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
About Chengdu Olymvax Biopharmaceuticals Inc.
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 496.12M | 547.48M | 487.15M | 320.11M | 179.11M | 76.34M | 14.59M | 161.28K | 419.32K | 83.58K | 498.17K |
| Cost of Revenue | 32.00M | 39.06M | 29.58M | 15.56M | 15.23M | 11.66M | 2.90M | 864.00 | 2.81K | 825.19 | 3.80K |
| Gross Profit | 464.12M | 508.42M | 457.57M | 304.55M | 163.88M | 64.67M | 11.69M | 160.42K | 416.52K | 82.75K | 494.36K |
| Gross Profit Ratio | 93.55% | 92.86% | 93.93% | 95.14% | 91.50% | 84.72% | 80.09% | 99.46% | 99.33% | 99.01% | 99.24% |
| Research & Development | 114.73M | 121.99M | 56.36M | 42.73M | 52.11M | 30.62M | 19.49M | 39.93M | 35.56M | 17.22M | 0.00 |
| General & Administrative | 26.84M | 30.20M | 17.16M | 9.88M | 19.10M | 6.67M | 5.86M | 54.86M | 52.38M | 21.96M | 21.19M |
| Selling & Marketing | 244.64M | 288.39M | 245.51M | 183.73M | 99.64M | 30.93M | 6.06M | 8.38K | 1.67K | 0.00 | 0.00 |
| SG&A | 271.49M | 318.60M | 262.67M | 193.62M | 118.75M | 37.60M | 11.91M | 54.87M | 52.38M | 21.96M | 21.19M |
| Other Expenses | 74.81M | 7.35M | 29.04M | 22.71M | 16.78M | 2.24M | 1.32M | 0.00 | 0.00 | 271.85K | 462.07K |
| Operating Expenses | 461.02M | 447.94M | 348.07M | 259.05M | 187.64M | 77.34M | 37.35M | 54.94M | 50.29M | 21.96M | 21.19M |
| Cost & Expenses | 493.02M | 487.00M | 377.65M | 274.61M | 202.87M | 89.01M | 40.26M | 54.94M | 50.30M | 21.96M | 21.19M |
| Interest Income | 2.55M | 3.85M | 1.42M | 374.70K | 341.88K | 40.32K | 140.80K | 750.20K | 2.48M | 0.00 | 0.00 |
| Interest Expense | 7.18M | 4.24M | 1.23M | 569.71K | 494.03K | 400.26K | 97.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 33.96M | 28.73M | 24.68M | 17.94M | 15.25M | 10.37M | 9.54M | 9.22M | 16.47M | 6.57M | 5.04M |
| EBITDA | 56.81M | 77.53M | 131.45M | 55.05M | -23.38M | -8.17M | -17.57M | -46.65M | -36.72M | -15.30M | -15.66M |
| EBITDA Ratio | 11.45% | 17.25% | 29.39% | 20.71% | -3.31% | -1.33% | -98.19% | -28,925.38% | -8,756.48% | -18,307.74% | -3,143.21% |
| Operating Income | 3.10M | 69.14M | 101.58M | 48.68M | -23.75M | -21.23M | -28.52M | -55.87M | -53.18M | -25.21M | -23.70M |
| Operating Income Ratio | 0.62% | 12.63% | 20.85% | 15.21% | -13.26% | -27.81% | -195.47% | -34,643.25% | -12,683.32% | -30,160.54% | -4,757.02% |
| Total Other Income/Expenses | 12.52M | 2.03M | 5.61M | 3.00M | 2.16M | 2.24M | 1.32M | 342.65K | 829.05K | 2.25M | 462.07K |
| Income Before Tax | 15.62M | 43.65M | 107.19M | 36.13M | -31.01M | -18.99M | -27.21M | -55.53M | -52.35M | -24.94M | -23.24M |
| Income Before Tax Ratio | 3.15% | 7.97% | 22.00% | 11.29% | -17.31% | -24.87% | -186.45% | -34,430.80% | -12,485.61% | -29,835.27% | -4,664.27% |
| Income Tax Expense | 4.18M | 17.07M | -773.65K | 12.55M | 33.11K | 19.50K | 31.79K | 0.00 | 0.00 | 3.33M | 3.00M |
| Net Income | 17.56M | 26.58M | 107.96M | 23.58M | -31.04M | -19.01M | -27.24M | -55.53M | -52.35M | -24.94M | -23.24M |
| Net Income Ratio | 3.54% | 4.85% | 22.16% | 7.37% | -17.33% | -24.90% | -186.67% | -34,430.80% | -12,485.61% | -29,835.27% | -4,664.27% |
| EPS | 0.04 | 0.07 | 0.27 | 0.06 | -0.08 | -0.09 | -0.13 | -0.29 | -0.31 | -0.18 | 0.00 |
| EPS Diluted | 0.04 | 0.07 | 0.27 | 0.06 | -0.08 | -0.09 | -0.13 | -0.29 | -0.31 | -0.18 | 0.00 |
| Weighted Avg Shares Out | 405.44M | 405.27M | 405.27M | 405.27M | 405.27M | 205.70M | 203.13M | 191.49M | 168.89M | 137.46M | 0.00 |
| Weighted Avg Shares Out (Dil) | 405.44M | 405.27M | 405.27M | 405.27M | 405.27M | 205.70M | 203.13M | 191.49M | 168.89M | 137.46M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports